Cagrilintide vs Pramlintide
Cagrilintide (Long-acting amylin receptor agonist (amylin analog)) and Pramlintide (Amylin analog) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Page updated 2026-09-20. Latest review of a source entry: 2026-09-20. Editorial method.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Cagrilintide | Pramlintide |
|---|---|---|
| Compound class | Long-acting amylin receptor agonist (amylin analog) | Amylin analog |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | ~3731 g/mol | Not documented |
| Half-life | ~7 days | Not documented |
| Origin | An investigational long-acting amylin analog developed by Novo Nordisk, studied both alone and in combination with semaglutide. It has been evaluated in clinical trials in the 2020s. | A 52-week randomized trial enrolled 656 insulin-treated people with type 2 diabetes and compared adjunctive pramlintide with placebo. The study assessed glucose control, body weight and adverse events. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Cagrilintide works
Cagrilintide is a modified, long-acting analog of the pancreatic hormone amylin that acts as an agonist at amylin and calcitonin receptors. Amylin signaling promotes satiety, slows gastric emptying, and reduces food intake through central and peripheral pathways distinct from the incretin (GLP-1) system. Structural modifications and acylation extend its half-life to support once-weekly administration.
How Pramlintide works
Pramlintide is an analog of amylin, a pancreatic hormone involved in post-meal glucose regulation. It is not a GLP-1 receptor agonist; it is grouped here for metabolic comparisons.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Cagrilintide
Pramlintide
What sets each apart
Cagrilintide
Cagrilintide is an amylin analog, not a GLP-1 or GIP agonist, so it acts through a different appetite-regulating pathway and is often studied in combination with incretin agents.
Pramlintide
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
Frequently asked questions
What is cagrilintide and what receptor class does it act on?
Cagrilintide (AM833) is a long-acting amylin analogue — it acts as an agonist at amylin and calcitonin receptors rather than the GLP-1 receptor. In research it is studied for satiety signaling, slowed gastric emptying, and body-weight effects, and it is the amylin half of the CagriSema combination. Its mechanism is complementary to, not overlapping with, GLP-1 agonists.
What is cagrilintide's half-life and dosing frequency?
Cagrilintide has a reported half-life of roughly 7-8 days (about 160-195 hours), thanks to lipid-modification-based half-life extension, which supports once-weekly administration in the literature. Its weekly kinetics make it a convenient partner for the weekly GLP-1 agonist semaglutide. Steady state is reached over several weeks of weekly dosing.
How is cagrilintide dose-escalated in the research literature?
A phase 2 program studied once-weekly doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg, using a dose-escalation period of up to about 6 weeks. In the reported data, effects on body weight were dose-dependent across that range. These are reference figures for research context only, not human dosing guidance.
What is the evidence context for Pramlintide?
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.
Linked publications
Publications recorded on each compound's profile, including original studies and reviews. These are background sources for the separate compounds; listing them together does not establish a direct comparison, a combination study, or equivalent evidence. Read the study design and limitations before interpreting a finding.